BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Salagre E, Grande I, Solé B, Sanchez-Moreno J, Vieta E. Vortioxetine: A new alternative for the treatment of major depressive disorder. Rev Psiquiatr Salud Ment (Engl Ed) 2018;11:48-59. [PMID: 28800937 DOI: 10.1016/j.rpsm.2017.06.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Goldstein Ferber S, Weller A, Yadid G, Friedman A. Discovering the Lost Reward: Critical Locations for Endocannabinoid Modulation of the Cortico-Striatal Loop That Are Implicated in Major Depression. Int J Mol Sci 2021;22:1867. [PMID: 33668515 DOI: 10.3390/ijms22041867] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Segura-Garcia C, Rania M, Carbone EA, de Filippis R, Aloi M, Caroleo M, Grasso G, Calabrò G, Fazia G, Staltari FA, Falvo A, Pugliese V, Gaetano R, Steardo L Jr, De Fazio P. Naturalistic and Uncontrolled Pilot Study on the Efficacy of Vortioxetine in Binge Eating Disorder With Comorbid Depression. Front Psychiatry 2021;12:635502. [PMID: 33815170 DOI: 10.3389/fpsyt.2021.635502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Alamo C, García-Garcia P, Lopez-Muñoz F, Zaragozá C. Tianeptine, an atypical pharmacological approach to depression. Rev Psiquiatr Salud Ment (Engl Ed) 2019;12:170-86. [PMID: 30612921 DOI: 10.1016/j.rpsm.2018.09.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
4 Alboni S, Benatti C, Colliva C, Radighieri G, Blom JMC, Brunello N, Tascedda F. Vortioxetine Prevents Lipopolysaccharide-Induced Memory Impairment Without Inhibiting the Initial Inflammatory Cascade. Front Pharmacol 2020;11:603979. [PMID: 33613281 DOI: 10.3389/fphar.2020.603979] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Vieta E, Florea I, Schmidt SN, Areberg J, Ettrup A. Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol 2019;34:153-60. [PMID: 31094901 DOI: 10.1097/YIC.0000000000000271] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
6 Naß J, Abdelfatah S, Efferth T. Ursolic acid enhances stress resistance, reduces ROS accumulation and prolongs life span in C. elegans serotonin-deficient mutants. Food Funct 2021;12:2242-56. [PMID: 33596295 DOI: 10.1039/d0fo02208j] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 Alcántara Montero A, Pacheco de Vasconcelos SR. Role of vortioxetine in the treatment of neuropathic pain. Rev Esp Anestesiol Reanim 2021:S0034-9356(21)00162-6. [PMID: 34243960 DOI: 10.1016/j.redar.2021.04.001] [Reference Citation Analysis]
8 Castellano S, Torrent C, Petralia MC, Godos J, Cantarella RA, Ventimiglia A, De Vivo S, Platania S, Guarnera M, Pirrone C, Drago F, Vieta E, Di Nuovo S, Popovic D, Caraci F. Clinical and Neurocognitive Predictors of Functional Outcome in Depressed Patients with Partial Response to Treatment: One Year Follow-Up Study. Neuropsychiatr Dis Treat 2020;16:589-95. [PMID: 32184600 DOI: 10.2147/NDT.S224754] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 de la Fuente-Tomas L, Sánchez-Autet M, García-Álvarez L, González-Blanco L, Velasco Á, Sáiz Martínez PA, Garcia-Portilla MP, Bobes J. Clinical staging in severe mental disorders; bipolar disorder, depression and schizophrenia. Rev Psiquiatr Salud Ment (Engl Ed) 2019;12:106-15. [PMID: 30314812 DOI: 10.1016/j.rpsm.2018.08.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
10 De Berardis D, Fornaro M, Anastasia A, Vellante F, Olivieri L, Rapini G, Serroni N, Orsolini L, Valchera A, Carano A, Tomasetti C, Ventriglio A, Bustini M, Pompili M, Serafini G, Perna G, Iasevoli F, Martinotti G, Di Giannantonio M. Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a "real-world" chart review study. Braz J Psychiatry 2020;42:317-21. [PMID: 32159712 DOI: 10.1590/1516-4446-2019-0690] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
11 Atique-ur-rehman H, Neill JC. Cognitive dysfunction in major depression: From assessment to novel therapies. Pharmacology & Therapeutics 2019;202:53-71. [DOI: 10.1016/j.pharmthera.2019.05.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
12 Gonda X, Sharma SR, Tarazi FI. Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. Expert Opinion on Drug Discovery 2018;14:81-9. [DOI: 10.1080/17460441.2019.1546691] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]